Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Aprepitant is currently approved for prophylaxis of acute and delayed CINV for highly
emetogenic chemotherapy regimens, including cisplatin; however, it has not yet been studied
in multiple-day chemotherapy treatment programs. This study will compare the addition of
aprepitant compared to placebo administered on days 3,4,5 of chemotherapy administration for
acute CINV prophylaxis with standard antiemetic prophylaxis and days 6 and 7 for delayed CINV
prophylaxis in a double-blind, randomized, crossover study design.